|
Response on prior anti-EGFR therapy
|
|
Response or stable disease ≥6 m
|
37/89 (42)
|
|
No response or stable disease <6 m
|
52/89 (58)
|
|
Clinical benefit on anti-EGFR retreatment
| |
|
Best response CR/PR/SD
|
50/86 (58)
|
|
Best response PD
|
36/86 (42)
|
|
Prior anti-EGFR-based regimens
| |
|
Panitumumab monotherapy
|
6/89 (7)
|
|
Panitumumab + Chemotherapya
|
9/89 (10)
|
|
Panitumumab and AMG-102/AMG-479
|
1/89 (1)
|
|
Cetuximab monotherapy
|
2/89 (2)
|
|
Cetuximab + Chemotherapyb
|
71/89 (80)
|
|
Anti-EGFR-based retreatment regimens
| |
|
Cetuximab, FOLFOX, and dasatinib
|
31/89 (35)
|
|
Cetuximab, irinotecan, and bevacizumab
|
12/89 (13)
|
|
Cetuximab and erlotinib
|
13/89 (15)
|
|
Cetuximab and sirolimus
|
11/89 (12)
|
|
Cetuximab, HAIc oxaliplatin, 5-FU, bevacizumab
|
20/89 (23)
|
|
Cetuximab, HAI oxaliplatin, and bevacizumab
|
2/89 (2)
|
|
Interval length between prior and retreatment anti-EGFR therapies
|
Months
|
|
Median
|
4.57
|
|
Mean ± Standard Deviation
|
7.34 ± 8.9
|
|
Range
|
0.46 – 58.7
|
